ABSTRACT
PURPOSE: The purpose of this study was to assess the treatment effect of extracorporeal magnetic innervation (ExMI) therapy, and determine how long the effect of this treatment lasts. MATERIALS AND METHODS: Among the demonstrable stress urinary incontinent patients, 28 were selected. Before the ExMI therapy, voiding diary, incontinence episodes, pad test, and quality of life questionnaires were evaluated. The treatment was performed for 30 minutes, 3 times a week, for 6 weeks. All of the evaluations were repeated at the first and sixth months following treatment. The treatment outcomes were classified as: cure, good, fair, poor and failure, according to a new outcome score. RESULTS: The overall cure rate was 35.7% (10/28) by the 1st month and 17.9% (5/28) by the 6th. From further a classification, the cure rate in grade I was 43.8 (7/16) and 25% (4/16) by the 1st and 6th months, respectively, and in grade II were 25 (3/12) and 8.3% (1/12) respectively. Incontinence episode was reduced from 4.2+/-2.8 to 1.5+/-1.5 and 2.8+/-2.3 by the 1st and 6th months, respectively. The urine loss was reduced from 21.0+/-31.4g to 6.0+/-8.2g and 14.0+/-24.7g by the 1st and 6th months, respectively. The results were statistically analyzed using Wilcoxon rank sum and Fisher's exact tests. CONCLUSIONS: It was suggested that the ExMI therapy was an effective treatment for stress urinary incontinence, but its effect decreased over time. In order to sustain, or improve its effect, a regular interval, or prolonged ExMI therapy, would be need
Subject(s)
Humans , Classification , Quality of Life , Surveys and Questionnaires , Urinary IncontinenceABSTRACT
PURPOSE: The purpose of this study is to assess if extracorporeal magnetic innervation (ExMI) can be successful in treating stress urinary incontinence (SUI). MATERIALS AND METHODS: We studied 38 women with demonstrable stress urinary incontinence. Evaluation before treatment included history, physical examination, voiding diary, perineometer that measures the strength and endurance of pelvic floor muscle contractions, urodynamic study and quality of life questionnaires. Treatments were performed for 20 minutes (10Hz for 10 minutes and 50Hz for 10 minutes), twice a week for 6 weeks. After ExMI therapy, all of the evaluations were repeated at the eighth week. RESULTS: The follow up care was continued on the patients for longer than 2 months. Fourteen out of the 38 patients (36%) were dry after the ExMI treatment. The frequency of leak episodes was reduced from 2.8 to 1.7 in 2 months. Pelvic floor muscle contraction (PMC) pressure was increased from 10.42 4.35 to 17.02 4.04mmHg. CONCLUSIONS: Our early results suggest that ExMI therapy is an effective approach for the treatment of SUI. However, longer follow-up is required to determine how long the benefits of treatment last, whether re-treatment will be necessary, and what the effective treatment strategies are.